# Kevin R Lynch

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 45 papers | 1,819 citations | 279701 23 h-index | 265120 42 g-index |
| 46 all docs | 46 docs citations | 46 times ranked | 2235 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Current Opinion in Immunology, 2002, 14, 569-575. | 2.4 | 259 |
| 2 | Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism, 2014, 3, 114-123. | 3.0 | 168 |
| 3 | Characterization of a human gene related to genes encoding somatostatin receptors. FEBS Letters, 1996, 398, 253-258. | 1.3 | 92 |
| 4 | Drugging Sphingosine Kinases. ACS Chemical Biology, 2015, 10, 225-233. | 1.6 | 87 |
| 5 | Sphingosine kinase typeÂ2 inhibition elevates circulating sphingosine 1-phosphate. Biochemical Journal, 2012, 447, 149-157. | 1.7 | 84 |
| 6 | Characterization of the Human and Mouse Sphingosine 1-Phosphate Receptor, S1P5 (Edg-8):â€‰Structureâ^'Activity Relationship of Sphingosine1-Phosphate Receptors. Biochemistry, 2001, 40, 14053-14060. | 1.2 | 79 |
| 7 | Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD. Blood, 2014, 124, 1941-1950. | 0.6 | 70 |
| 8 | Life on the edg. Trends in Pharmacological Sciences, 1999, 20, 473-475. | 4.0 | 69 |
| 9 | Sphingosine kinase typeÂ1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochemical Journal, 2011, 440, 345-353. | 1.7 | 68 |
| 10 | Structureâ^'Activity Relationship Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase Inhibitors: Discovery of SphK1- and SphK2-Selective Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 1879-1899. | 2.9 | 67 |
| 11 | Sphingosine Kinase 2 Inhibition and Blood Sphingosine 1-Phosphate Levels. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 23-31. | 1.3 | 59 |
| 12 | Sphingosine Kinase 2 Deficiency Attenuates Kidney Fibrosis via IFN-Î³. Journal of the American Society of Nephrology: JASN, 2017, 28, 1145-1161. | 3.0 | 59 |
| 13 | Lysophospholipid receptor nomenclature. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1582, 70-71. | 1.2 | 50 |
| 14 | Cloning and expression of a bovine adenosine A1receptor cDNA. FEBS Letters, 1992, 297, 107-111. | 1.3 | 49 |
| 15 | Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1245-L1252. | 1.3 | 48 |
| 16 | Structureâ€“activity relationships of lysophosphatidic acid analogs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1582, 289-294. | 1.2 | 42 |
| 17 | Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity. Journal of Medicinal Chemistry, 2017, 60, 3933-3957. | 2.9 | 36 |
| 18 | Photoacoustic microscopy reveals the hemodynamic basis of sphingosine 1-phosphate-induced neuroprotection against ischemic stroke. Theranostics, 2018, 8, 6111-6120. | 4.6 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Structure/Activity Relationships in Lysophosphatidic Acid: The 2-Hydroxyl Moiety. Molecular Pharmacology, 1997, 52, 75-81. | 1.0 | 33 |
| 20 | Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning. Acta Biomaterialia, 2014, 10, 4704-4714. | 4.1 | 32 |
| 21 | A rapid assay for assessment of sphingosine kinase inhibitors and substrates. Analytical Biochemistry, 2011, 411, 230-235. | 1.1 | 29 |
| 22 | Sphingosine 1-phosphate chemical biology. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 508-512. | 1.2 | 24 |
| 23 | Sphingosine kinase inhibitors: a review of patent literature (2006-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1409-1416. | 2.4 | 24 |
| 24 | Mechanism of sphingosine 1-phosphate clearance from blood. Biochemical Journal, 2020, 477, 925-935. | 1.7 | 23 |
| 25 | Trypsin induces Ca2+-activated Clâ^'currents inX. laevisoocytes. FEBS Letters, 1994, 337, 235-238. | 1.3 | 22 |
| 26 | Structureâ^'Activity Relationships of Lysophosphatidic Acid:â€‰ Conformationally Restricted Backbone Mimetics. Journal of Medicinal Chemistry, 1999, 42, 963-970. | 2.9 | 22 |
| 27 | Structureâ€“Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 229-234. | 1.3 | 21 |
| 28 | Decreased Peritoneal Ovarian Cancer Growth in Mice Lacking Expression of Lipid Phosphate Phosphohydrolase 1. PLoS ONE, 2015, 10, e0120071. | 1.1 | 21 |
| 29 | Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles. ACS Medicinal Chemistry Letters, 2016, 7, 487-492. | 1.3 | 19 |
| 30 | Building a better sphingosine kinase-1 inhibitor. Biochemical Journal, 2012, 444, e1-e2. | 1.7 | 17 |
| 31 | Effect of alkyl chain length on sphingosine kinase 2 selectivity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6817-6820. | 1.0 | 17 |
| 32 | Structureâ€“activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4956-4960. | 1.0 | 16 |
| 33 | Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity. Journal of Medicinal Chemistry, 2020, 63, 1178-1198. | 2.9 | 15 |
| 34 | The Omnific Lysophospholipid Growth Factors. Annals of the New York Academy of Sciences, 2006, 905, xi-xiv. | 1.8 | 12 |
| 35 | Biosynthesis of alkyl lysophosphatidic acid by diacylglycerol kinases. Biochemical and Biophysical Research Communications, 2012, 422, 758-763. | 1.0 | 12 |
| 36 | Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 7656-7681. | 2.9 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3. Scientific Reports, 2017, 7, 127. | 1.6 | 9 |
| 38 | Lipophilic tail modifications of 2-(hydroxymethyl)pyrrolidine scaffold reveal dual sphingosine kinase 1 and 2 inhibitors. Bioorganic and Medicinal Chemistry, 2021, 30, 115941. | 1.4 | 9 |
| 39 | Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors. PLoS ONE, 2018, 13, e0192179. | 1.1 | 6 |
| 40 | Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors. European Journal of Medicinal Chemistry, 2021, 212, 113121. | 2.6 | 4 |
| 41 | A Novel Sphingosine Kinase Inhibitor Suppresses Chikungunya Virus Infection. Viruses, 2022, 14, 1123. | 1.5 | 1 |
| 42 | Sphingosine Kinase 2 Inhibitors: Rigid Aliphatic Tail Derivatives Deliver Potent and Selective Analogues. ACS Bio & Med Chem Au, 2022, 2, 469-489. | 1.7 | 1 |
| 43 | Cord Blood Plasma Enhances Migration of Hematopoietic Stem and Progenitor Cells (HSPC). Blood, 2011, 118, 2959-2959. | 0.6 | 0 |
| 44 | Opioid/sphingosineâ€1â€phosphate1 (S1P1) interactions in antinociception. FASEB Journal, 2012, 26, 1041.5. | 0.2 | 0 |
| 45 | Distinct generation, pharmacology, and distribution of sphingosine 1â€phosphate and dihydroâ€sphingosine 1â€phosphate in human neural progenitor cells. FASEB Journal, 2012, 26, 674.3. | 0.2 | 0 |